Impact of APP-assisted Patient Management on the Quality Control of Blood Purification Therapy
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorYunfeng Xia
About this trial
Many maintenance hemodialysis (MHD) patients develop negative outlooks due to their illnesses and complications, making their quality of life and prognosis a clinical concern. Effective life management and treatment cooperation are crucial to improving dialysis quality and patient outcomes. This trial aims to evaluate whether management through the "Yueya" mini-program and WeChat can provide personalized guidance such as health education, diet, exercise, medication supervision, and condition monitoring to enhance treatment compliance, quality of life, strengthen quality control in the hemodialysis unit, and improve patient prognosis.
Patients will be divided into a group receiving support via the "Yueya" mini-program and WeChat, and a control group receiving routine care. Clinical and laboratory indicators, cardiovascular events, death, hospitalization, quality of life, and compliance will be recorded and compared between groups to assess the impact of APP-assisted patient management on the quality of MHD blood purification therapy and the prognosis of MHD patients.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients with stage 5 chronic kidney disease, who have received maintenance hemodialysis for more than 3 months, are aged between 18 and 75 years old, and have regular dialysis three times a week.
Patients with relatively stable condition, who are able to take care of themselves and willing to cooperate with the study.
Patients who can understand and proficiently use WeChat and the "Yueya" mini - program used in this study.
Disqualifiers
Patients with communication barriers or other conditions that prevent them from cooperating with the study.
Patients who have a history of acute myocardial infarction, cerebral infarction or intracerebral hemorrhage in the past six months.
Patients who are not willing to actively cooperate with the study.
Patients with severe liver cirrhosis, active tuberculosis and AIDS.
Trial design
Design model
Parallel
Treatments tested in this trial
APP-based management
BehavioralBased on patients' specific conditions such as age, gender, primary disease, and complications, the APP-based management will provide individualized and round-the-clock guidance for dialysis patients in their daily lives through the "Yueya" mini-program and WeChat. This guidance covers various aspects, including health knowledge education, diet and exercise guidance, medication supervision, condition monitoring, and real-time feedback.
Treatment groups
392 Participants
are divided into 2 treatment groupsGroup A: APP management groupExperimental treatment 1 intervention
Group B: Non-APP management groupNo intervention 0 interventions
Trial outcomes
Primary outcomes
1
mortality rate
In this study, mortality rate was used as a prognostic indicator.
Time frame
About 1 year2
Hospitalization rate
In this study, the hospitalization rate was used as a prognostic indicator.
Time frame
About 1 year3
Kidney Disease Quality of Life
Measuring the quality of life of hemodialysis patients through the Kidney Disease Quality of Life-36（KDQOL-36） scale. If the KDQOL-36 score increases, the quality of life is considered to be improved.
Time frame
About 1 year4
Incidence of cardiovascular events
Time frame
About 1 yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Yunfeng Xia
Lead sponsor
First Affiliated Hospital of Chongqing Medical University
Sponsor institution
Source ClinicalTrials.gov